155 S. Limerick Road
411 articles with Teleflex Incorporated
Minimally Invasive UroLift System Treatment Provides Rapid Symptom Relief and Improved Quality of Life, While Preserving Sexual Function*1,2
Liam Kelly, President and CEO, Teleflex Incorporated, is scheduled to speak at the Raymond James 40th Annual Institutional Investors Conference at the JW Marriott Grande Lakes in Orlando, Florida on Tuesday, March 5, 2019 at 4:00 p.m..
NeoTract Announces Expanded Coverage for UroLift System Treatment for Patients with Enlarged Prostate
Favorable Coverage Decisions Broaden Access to This Minimally Invasive Treatment That Provides Rapid Relief and Recovery from Symptoms
Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, February 21, 2019
Teleflex Incorporated has announced that it received premarket approval from the U.S. Food and Drug Administration for the MANTA™ Vascular Closure Device
ACTO Emerges as a Leader in Life Sciences Commercialization; Closes Strong Calendar Year 2018 with 184% Revenue Growth and Doubled Customer Base
This past year, ACTO secured global, innovative pharmaceutical, medical device, and dental companies like Kala Pharmaceuticals, Teleflex, and Kulzer Dental US as clients.
Teleflex to Showcase the MANTA™ Vascular Closure Device from the Recently Acquired Essential Medical, Inc. at the Annual Meeting of the Leipzig Interventional Course (LINC) 2019, in Leipzig, Germany, on January 22-25
Teleflex Incorporated surgical and cardiac care, will showcase the MANTA™ Vascular Closure Device as well as its portfolio for peripheral interventions at the Annual Meeting of the Leipzig Interventional Course (LINC) 2019, in Leipzig, Germany.
NeoTract Study Finds That Men Over 40 Are Not Aware that Delaying Treatment of Benign Prostatic Hyperplasia (BPH) Can Cause Permanent Bladder Damage or of Treatment Options
Liam Kelly, President and CEO, Teleflex Incorporated (NYSE:TFX), is scheduled to speak at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California, on Tuesday, January 8, 2019 at 12:00 p.m. (PT).
For the second year in a row, Teleflex earned a top spot as a best place to work by US sales professionals in the annual MedReps.com Best Places to Work Survey.
Teleflex Announces Expanded “Family-Friendly” Benefits Beginning January 1, 2019 to Meet the Diverse Needs of Its Employees
Child-Bearer Parental Leave Support expanded by 300%, from 6 Weeks to 18 Weeks
Teleflex Incorporated announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock.
Third Quarter Revenues of $609.7 million, up 14.0% Versus Prior Year Period; up 15.0% on Constant Currency Basis
Teleflex Receives 2018 Medical Design Excellence Award (MDEA) for Arrow® AC3 OptimusTM Intra-Aortic Balloon Pump
Teleflex Incorporated has been selected as the bronze winner in the cardiovascular device category of the 20th annual Medical Design Excellence Awards competition.
NeoTract Welcomes UK Government Announcement to Remove Barriers to Adoption of the UroLift® System for BPH Care for Every NHS Hospital in England
A new Government scheme announced today selects the UroLift® System as one of seven innovations across all specialisms that are the most transformative for NHS patients
Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, November 1, 2018
Agreement gives Teleflex access to Arcis’ nucleic acid sample preparation technology
Acquisition expands presence in structural heart and endovascular aneurysm repair markets by adding unique large bore closure system
NeoTract Announces Multiple Data Presentations from Studies of UroLift® System Treatment for Enlarged Prostate at the World Congress of Endourology
Chief Technical Officer Ted Lamson to Receive Prestigious Industry Award for Innovation
Teleflex to Support Responding to Cardiac Arrest at ERC Congress, Resuscitation 2018, in Bologna, Italy from September 20th – 22nd
Teleflex Incorporated today announced that during the ERC Congress, it will focus on the Arrow® EZ-IO® Intraosseous Access System and on the campaign “What could 10 seconds to vascular access mean to your cardiac arrest patient?”